Pharmacophore-based virtual screening: A review of recent applications

Expert Opinion on Drug Discovery

Volumn 5, Issue 3, 2010, Pages 205-222

  Kim, Kyun Hwan ^a,b   Kim, Nam Doo ^c   Seong, Baik Lin ^d  

^a Konkuk University School of Medicine   (South Korea)

^b Konkuk University   (South Korea)

^c Equispharm Co Ltd   (South Korea)

^d Yonsei University   (South Korea)

Author keywords

Anticancer; Antivirus; Drug discovery; Pharmacophore; Virtual screening

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AROMATASE; AROMATASE INHIBITOR; AURORA A KINASE; CANNABINOID 1 RECEPTOR; CHECKPOINT KINASE 1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; NOOTROPIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; TAU PROTEIN; TUBULIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2; VIRUS ENZYME;

DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW;

EID: 77749326688     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441003592072     Document Type: Review

References (93)

1. Langer T, Krovat EM. Chemical featurebased pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Devel 2003;6(3):370-376
2. Wolber G, SeiDel T, Bendix F, et al. Molecule-pharmacophore superpositioning and pattern matching in computational drug Design. Drug Discov Today 2008;13(1-2):23-29
3. Wermuth CG. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. In pharmacophores and pharmacophore searches. vol.32; Wiley-VCH, 2006. p. 3-13
4. Hou T, Wang J, Zhang W, et al. Recent advances in computational prediction of drug absorption and permeability in drug discovery. Curr Med Chem 2006;13(22):2653-2667
5. Dror O, Shulman-Peleg A, Nussinov R, et al. Predicting molecular interactions in silico: I. A guiDe to pharmacophore iDentification and its applications to drug Design. Curr Med Chem 2004;11(1):71-90
6. Catalyst, Accelrys. Available from: http://www.accelrys.com
7. DISCO, Tripos, Inc. Available from: http://www.tripos.com
8. GASP, Tripos, Inc. Available from: http://www.tripos.com
9. Phase, Schrodinegr, Inc. Available from: http://www.schrodinger.com
10. Molecular Operating Environment (MOE), Chemical Computing Group. Available from: http://www. chemcomp.com
11. Wolber G, Langer T. LigandScout: 3-D pharmacophores Derived from proteinbound ligands and their use as virtual screening filters. J Chem Inf MoDel 2005;45:160-169
12. CONCORD, Tripos, Inc. Available from: http://www.tripos.com
13. CORINA, Molecular-networks. Available from: http://www.molecular- networks.De
14. MacromoDel, Schrodinger. Available from: http://www.schrodinger.com
15. Confort, Tripos, Inc. Available from: http://www.tripos.com
16. Hou T, Xu X. Recent Development and application of virtual screening in drug discovery: an overview. Curr Pharm Des 2004;10(9):1011-1033
17. Sun H. Pharmacophore-based virtual screening. Curr Med Chem 2008;15(10):1018-1024
18. KÎppen H. Virtual screening-what does it give us? Curr Opin Drug Discov Devel 2009;12(3):397-407
19. GÏner OF. History and evolution of the pharmacophore concept in computer-aiDed drug Design. Curr Top Med Chem 2002;2(12):1321-1332
20. GÏner O, Clement O, Kurogi Y. Pharmacophore moDeling and three dimensional database searching for drug Design using catalyst: recent advances. Curr Med Chem 2004;11(22):2991-3005
21. Khedkar SA, MalDe AK, Coutinho EC, et al. Pharmacophore moDeling in drug discovery and Development: an overview. Med Chem 2007;3(2):187-197
22. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11(5):494-502
23. Lyne PD. Structure-based virtual screening: an overview. Drug Discov Today 2002;7(20):1047-1055
24. Ravikumar M, Pavan S, Bairy S, et al. Virtual screening of cathepsin k inhibitors using docking and pharmacophore moDels. Chem Biol Drug Des 2008;72(1):79-90
25. Li HF, Lu T, Zhu T, et al. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore moDel of substituted ureas. Eur J Med Chem 2009;44(3):1240-1249
26. Toba S, Srinivasan J, Maynard AJ, et al. Using pharmacophore moDels to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR. J Chem Inf MoDel 2006;46(2):728-735
27. Zou J, Xie HZ, Yang SY, et al. Towards more accurate pharmacophore moDeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore moDel of CDK2. J Mol Graph MoDel 2008;27(4):430-438
28. Xie HZ, Li LL, Ren JX, et al. Pharmacophore moDeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for iDentifying novel inhibitors. Bioorg Med Chem Lett 2009;19(7):1944-1949
29. Xie QQ, Xie HZ, Ren JX, et al. Pharmacophore moDeling studies of type I and type II kinase inhibitors of Tie2. J Mol Graph MoDel 2009;27(6):751-758
30. Chen JJ, Liu TL, Yang LJ, et al. Pharmacophore moDeling and virtual screening studies of checkpoint kinase 1 inhibitors. Chem Pharm Bull (Tokyo) 2009;57(7):704-709
31. Krovat EM, FrÏhwirth KH, Langer T. Pharmacophore iDentification, in silico screening, and virtual library Design for inhibitors of the human factor Xa. J Chem Inf MoDel 2005;45(1):146-159
32. Zhu T, Jiao Y, Chen YD, et al. Pharmacophore iDentification of Raf-1 kinase inhibitors. Bioorg Med Chem Lett 2008;18(7):2346-2350
33. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-265
34. Chiang YK, Kuo CC, Wu YS, et al. Generation of ligand-based pharmacophore moDel and virtual screening for iDentification of novel tubulin inhibitors with potent anticancer activity. J Med Chem 2009;52(14):4221-4233
35. Liou JP, Mahindroo N, Chang CW, et al. Structure-activity relationship studies of 3-aroylindoles as potent antimitotic Agents. Chem Med Chem 2006;1(10):1106-1118
36. Kim do Y, Kim KH, Kim ND, et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding moDel with tubulin. J Med Chem 2006;49(19):5664-5670
37. Weisenberg RC, Borisy GG, Taylor EW. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 1968;7:4466-4479
38. Edwards ML, Stemerick DM, Sunkara PS. Chalcones: a new class of antimitotic agents. J Med Chem 1990;33:1948-1954
39. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4(12):927-936
40. Deng XQ, Wang HY, Zhao YL, et al. Pharmacophore moDeling and virtual screening for iDentification of new Aurora-A kinase inhibitors. Chem Biol Drug Des 2008;71:533-539
41. Boyer SJ. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Curr Top Med Chem 2002;2:972-1000
42. Yu H, Wang Z, Zhang L, et al. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore moDeling, virtual screening and docking studies. Chem Biol Drug Des 2007;69(3):204-211
43. Barnum D, Greene J, Smellie A, et al. IDentification of common functional configurations among molecules. J Chem Inf Comput Sci 1996;36:563-571
44. Miyazaki Y, Matsunaga S, Tang J, et al. Novel 4-amino-furo[2,3-d] pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg Med Chem Lett 2005;15(9):2203-2207
45. Lyne PD, Kenny PW, Cosgrove DA, et al. IDentification of compounds with nanomolar binding affinity for heckpoint Kinase-1 using knowledge-based virtual screening. J Med Chem 2004;47:1962-1968
46. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408(6811):433-439
47. Hindle SA, Rarey M, Buning C, et al. Flexible docking unDer pharmacophore type constraints. J Comput AiDed Mol Des 2002;16(2):129-149
48. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Eng J Med 2003;348(24):2431-2442
49. Neves MA, Dinis TC, Colombo G, et al. An efficient steroid pharmacophore-based strategy to iDentify new aromatase inhibitors. Eur J Med Chem 2009;44(10):4121-4127
50. Dayam R, Al-Mawsawi LQ, Zawahir Z, et al. Quinolone 3-carboxylic acid pharmacophore: Design of second generation HIV-1 integrase inhibitors. J Med Chem 2008;51(5):1136-1144
51. Barreca ML, Rao A, De Luca L, et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 2004;44(4):1450-1455
52. De Luca L, Barreca ML, Ferro S, et al. Pharmacophore-based discovery of smallmolecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem Med Chem 2009;4(8):1311-1316
53. Mustata GI, Brigo A, Briggs JM. HIV-1 integrase pharmacophore moDel Derived from diverse classes of inhibitors. Bioorg Med Chem Lett 2004;14(6):1447-1454
54. Pandit D, So SS, Sun H. Enhancing specificity and sensitivity of pharmacophorebased virtual screening by incorporating chemical and shape features-a case study of HIV protease inhibitors. J Chem Inf MoDel 2006;46(3):1236-1244
55. Steindl TM, Schuster D, Laggner C, et al. Parallel screening and activity profiling with HIV protease inhibitor pharmacophore moDels. J Chem Inf MoDel 2007;47(2):563-571
56. Përez-Nueno VI, Pettersson S, Ritchie DW, et al. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J Chem Inf MoDel 2009;49(4):810-823
57. Discovery Studio, Accelrys. Available from: http://www.accelrys.com
58. Ryu K, Kim ND, Choi SI, et al. IDentification of novel inhibitors of HCV RNADepenDent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorg Med Chem 2009;17(8):2975-2982
59. Melagraki G, Afantitis A, Sarimveis H, et al. IDentification of a series of novel Derivatives as potent HCV inhibitors by a ligand-based virtual screening optimized procedure. Bioorg Med Chem 2007;15(23):7237-7247
60. Corbeil CR, Englebienne P, Yannopoulos CG, et al. Docking ligands into flexible and solvated macromolecules. 2. Development and application of fitted 1.5 to the virtual screening of potential HCV polymerase inhibitors. J Chem Inf MoDel 2008;48(4):902-909
61. Kim J, Kim KS, Kim DE, et al. IDentification of novel HCV RNA-DepenDent RNA polymerase inhibitors using pharmacophore-guiDed virtual screening. Chem Biol Drug Des 2008;72(6):585-591
62. Steindl T, Langer T. Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening. J Chem Inf Comput Sci 2004;44(5):1849-1856
63. Kim J, Lee C, Chong Y. IDentification of potential influenza virus endonuclease inhibitors through virtual screening based on the 3D-QSAR moDel. SAR QSAR Environ Res 2009;20(1):103-118
64. Zhang XW, Yap YL, Altmeyer RM. Generation of predictive pharmacophore moDel for SARS-coronavirus main proteinase. Eur J Med Chem 2005;40(1):57-62
65. Sirois S, Wei DQ, Du Q, et al. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J Chem Inf Comput Sci 2004;44(3):1111-1122
66. Tsai KC, Chen SY, Liang PH, et al. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006;49(12):3485-3495
67. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88(12):, 5593-5602
68. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolicsyndrome: Report of the National Heart, Lung, and Blood Institute/American HeartAssociation conference on scientific issues related to Definition. Circulation 2004;109(3):433-438
69. Yang H, Dou W, Lou J, et al. Discovery of novel inhibitors of 11beta-hydroxysteroid Dehydrogenase type 1 by docking and pharmacophore moDeling. Bioorg Med Chem Lett 2008;18(4):1340-1345
70. Yang H, Shen Y, Chen J, et al. Structure- based virtual screening for iDentification of novel 11beta-HSD1 inhibitors. Eur J Med Chem 2009;44(3):1167-1171
71. Rafferty SP, Guillemette JG, Berghuis AM, et al. Mechanistic and structural contributions of critical surface and internal residues to cytochrome c electron transfer reactivity. Biochemistry 1996;35(33):10784-10792
72. GLIDE, Schrodinger. Available from: http://www.schrodinger.com
73. Schuster D, Maurer EM, Laggner C, et al. The discovery of new 11betahydroxysteroid Dehydrogenase type 1 inhibitors by common feature pharmacophore moDeling and virtual screening. J Med Chem 2006;49(12):3454-3466
74. Wang H, Duffy RA, Boykow GC, et al. IDentification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore moDel. J Med Chem 2008;51(8):2439-2446
75. Foloppe N, Benwell K, Brooks TD, et al. Discovery and functional evaluation of diverse novel human CB(1) receptor ligands. Bioorg Med Chem Lett 2009;19(15):4183-4190
76. Ward RA, Perkins TD, Stafford J. Structure- based virtual screening for low molecular weight chemical starting points for dipeptidyl peptidase IV inhibitors. J Med Chem 2005;48(22):6991-6996
77. Lyne PD, Kenny PW, Cosgrove DA, et al. IDentification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J Med Chem 2004;47(8):1962-1968
78. OMEGA, Openeye Science. Available from: http://www.openeyes.com
79. Stockel-Maschek A, Mrestani-Klaus C, Stiebitz B, et al. Thioxo amino acid pyrrolidiDes and thiazolidiDes: new inhibitors of proline specific peptidases. Biochim Biophys Acta 2000;1479(1-2):15-31
80. Xu HE, Lambert MH, Montana VG, et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 1999;3:397-403
81. Markt P, Petersen RK, Flindt EN, et al. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore moDeling, 3D shape, and electrostatic similarity screening. J Med Chem 2008;51(20):6303-6317
82. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:35-242
83. Clement OO, Mehl AT. HipHop: pharmacophores based on multiple commonfeature alignments. In: Pharmacophore perception, Development, and use in drug Design. International University Line, La Jolla, CA, 2000. p. 71-84
84. Pipeline Pilot, Scitegic. Available from: http://www.scitegic.com
85. ROCS, Openeye Scientific Software, Inc. Available from: http://www.openeyes.com
86. EON, Openeye Scientific Software, Inc. Available from: http://www.openeyes.com
87. Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173- 176
88. Tikhonova IG, Sum CS, Neumann S, et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 2008;51(3):625-633
89. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf MoDel 2005;45(1):177-182
90. Larbig G, Pickhardt M, Lloyd DG, et al. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res 2007;4(3):315-323
91. Pickhardt M, von Bergen M, Gazova Z, et al. Screening for inhibitors of tau polymerization. Curr Alzheimer Res 2005;2(2):219-226
92. Dror O, Schneidman-Duhovny D, Inbar Y, et al. Novel approach for efficient pharmacophore-based virtual screening: method and applications. J Chem Inf MoDel 2009;49(10):2333-2343
93. Schneidman-Duhovny D, Dror O, Inbar Y, et al. Deterministic pharmacophore Detection via multiple flexible alignment of drug-like molecules. J Comput Biol 2008;15(7):737-754